Sponsor or institution
Clinical trials and research at Hangzhou Huasai Biomedicine Co., Ltd.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Hangzhou Huasai Biomedicine Co., Ltd. that are recruiting, in China. By phase: Phase 1 (4), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| HS-IT101 TIL therapy for advanced NSCLC in a single-arm study | Phase 1 | Shanghai | Recruiting | Sep 21, 2026 |
| Immune cell therapy for advanced clear cell kidney cancer | Phase 1 | Beijing and 1 other locations | Recruiting | Aug 18, 2026 |
| Autologous TIL therapy (HS-IT101) vs chemo in advanced melanoma | Phase 2 | Beijing | Recruiting | Feb 12, 2026 |
| HS-IT101 Injection for Advanced NSCLC: a one-arm cell therapy approach | Phase 1 | Guangzhou, Guangdong | Recruiting | Aug 5, 2025 |
| Injection of HS-IT101 for advanced solid tumors | Phase 1 | Beijing, Beijing Municipality | Recruiting | Apr 2, 2024 |
All recruiting trials (5)
-
HS-IT101 TIL therapy for advanced NSCLC in a single-arm study
This study tests HS-IT101, a patient’s own tumor-infiltrating lymphocytes, given after conditioning with drugs and IL-2, in adults with advanced non-small cell lung cancer who have exhausted standard treatments.
-
Immune cell therapy for advanced clear cell kidney cancer
This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.
-
Autologous TIL therapy (HS-IT101) vs chemo in advanced melanoma
This study tests whether a single infusion of a patient’s own tumor-infiltrating lymphocytes (HS-IT101) helps people with advanced melanoma more than the doctor’s chemotherapy choice after other treatments have failed.
-
HS-IT101 Injection for Advanced NSCLC: a one-arm cell therapy approach
This study tests whether a patient’s own tumor-infiltrating lymphocytes, given after conditioning with chemotherapy, can be safely given to adults with advanced non-small cell lung cancer.
-
Injection of HS-IT101 for advanced solid tumors
This study is testing a new treatment using patients' own immune cells to see if it can help people with advanced solid tumors feel better.
Quick answers
How many clinical trials run by Hangzhou Huasai Biomedicine Co., Ltd. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.